The prevention and treatment of infectious diseases is highly dependent on the availability of reliable diagnostic tests and protective or therapeutic vaccines. There also exists an urgent need to develop reliable biomarkers to monitor treatment success and to predict disease progression from asymptomatic to symptomatic disease in several infectious diseases. The elucidation of the disease-relevant antigens that elicit the protective immune responses is critical and required for the development of diagnostics and treatments. Here we present a novel "T cell driven approach" that permits the direct identification of pathogen epitopes and protein antigens capable of triggering specific T cell responses upon immunization in humans.
Introduction
The elucidation of the disease-relevant antigens that elicit protective immune responses is critical and required for the development of diagnostics and treatments. Here we present a novel "T cell driven approach" that permits the direct identification of pathogen epitopes and protein antigens that trigger specific T cell responses upon immunization in humans. This approach includes a single pathogen in vitro stimulation, the generation of pathogen specific T cell clones, the evaluation of their specificity by multiple cytokine production, and the screening of the clones with positional scanning peptide libraries. PBMC from smallpox vaccinated donors were used to generate vaccinia specific CD4+ T cell clones. The peptide specificity of these T cells was elucidated in a completely unbiased fashion by screening each of the clones with positional scanning libraries composed in total of trillions of peptides. Ten novel epitopes and their corresponding protein antigens from vaccinia virus that trigger CD4+ responses upon smallpox vaccination in humans were identified. GM-CSF, while not a standard cytokine used for monitoring T cell responses against vaccines or infections, was found to require lower antigen concentration for its production than other cytokines, such as IFN-γ, IL-2, and TNF-α. Furthermore, a comprehensive analysis of the reported immunogenicity of the vaccinia proteins is presented.
Results
The overall approach presented in this study is summarized in Figure 1 . The approach is T cell driven because it is centered on the expansion and characterization of T cells in response to the vaccine or pathogen of interest. The elucidation of the specificity of the T cells is carried out using positional scanning libraries composed of peptides that represent an unbiased source of antigens. The combination of the screening results of the positional scanning and a biometrical analysis leads to the elucidation of the peptide and antigen specificity.
One of the main obstacles to the study of antigen-specific human T cells is their low frequency in PBMC samples. To overcome this, CD4+ T cell lines specific to vaccinia virus were generated to expand, at least in part, the vaccinia specific T cells that were generated in vivo upon immunization. In this regard we [1] and others [2] have shown that pathogen-specific T cells from infected or immunized subjects are successfully expanded with a single in vitro stimulation with the pathogen. Figure 2 shows the comparison on the frequency of pathogen-specific cells in ex vivo PBMC and in vaccinia-stimulated lines. The percentage of vaccinia specific T cells was determined by intracellular staining of TNF-α and IFN-γ production upon vaccinia stimulation. Clearly, in the vaccinia-stimulated line the frequency of cytokine producing CD4 + and CD8 + T cells was successfully expanded.
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Once T cell lines are generated, the second step is the generation of T cell clones by limiting dilution following expansion using phytohemagglutinin (PHA) and allogeneic feeders. Clones that grow to large numbers (> 5 million cells) are characterized for clonality by flow cytometry using a panel of anti-Vβ T cell receptor antibodies. A fundamental part of the analysis is the choice of the readout that will be used to determine if a given T cell line or clone is specific to the pathogen of interest. In this regard, and as part of this study, we have shown the importance of evaluating a large number of cytokines, and not only IFN-γ as it has been reported in the majority of vaccinia T cell specificity studies. The evaluation of 22 cytokines was carried out using the multiplex assay and resulted in the selection of 6 cytokines (GM-CSF, IFN-γ, IL-2, IL-4, IL-13 and TNF-α) to characterize the specificity of vaccinia clones [1] . The advantage of using TNF-α and GM-CSF instead of IFN-γ for the selection of vaccinia specific clones is clearly shown in Figure 3 . Figure 3A and 3B show the number of positive clones, and their corresponding percentage, that were identified by ELISA and Multiplex assay, respectively. Only 10% of the 87 clones tested by ELISA and 24% of the 28 clones tested by Multiplex assay produced IFN-γ. These results clearly illustrate the importance of using TNF-α and GM-CSF production as readouts of vaccinia CD4 T cell responses since the large majority of the clones would have been missed if only IFN-γ would have been monitored. Furthermore, we found that the detection of GM-CSF in response to mixtures of a positional scanning library represents a reliable and optimal readout. In addition, the determination of cytokine production at decreasing concentration of the peptides, identified using the positional scanning library, showed that the production of GM-CSF requires less peptide than TNF-α as well as other cytokines [1] . We are currently characterizing the immune response to other infections evaluating various cytokines by multiplex assay and GM-CSF and TNF-α are among the cytokines that appear to be important.
Once clones are selected based on their specificity to the pathogen of interest and once they are grown to large numbers they are screened with positional scanning libraries in order to determine the epitope and protein specificity. In our recently published vaccinia specificity study, 10 novel epitopes and their corresponding protein antigens from vaccinia virus that trigger CD4+ responses upon smallpox vaccination in humans were identified [1] . We have evaluated and compared the performance efficacy of T cell driven approaches (including ours), and MHC approaches that have been reported by others in the elucidation of vaccinia epitopes recognized by human CD4+ T cells. This analysis takes advantage of the multiple reports on vaccinia specificity and was carried by compiling the reported vaccinia CD4+ epitopes and the recognition of the vaccinia proteins by human CD4+ T cells [3] and antibodies [3] [4] [5] [6] [7] . Each of the vaccinia proteins was assigned a percentage of recognition that was determined by dividing the number of subjects that showed protein recognition by the total number of subjects tested (76 or 126 for antibodies and 11 for T cells). Based on the overall distribution of recognition (shown on the top graphs of Figure  4 ) and the number of subjects tested we established a cutoff for a protein to be considered predominantly recognized. This cutoff resulted in >40% and >10% for CD4+ T cell or antibody responses, respectively. Using these thresholds 31 out of 180 proteins were determined as predominantly recognized by CD4+ T cells and 21 by antibodies. In addition, the compilation of all the reported vaccinia epitopes recognized by human CD4+ T cells using T cell and MHC driven approaches revealed that epitopes have been identified for 25 and 48 vaccinia proteins, respectively. The percent of recognition for the proteins for which epitopes have been reported using T cell approaches and MHC approaches are shown in the middle and bottom bar graphs respectively in Figure 4 . The proteins that we have identified using the approach presented in this study are: D13L, F13L, H5R, A10L, L1R, A7L, A6L, E1L, A28L and D1R (denoted with * in the middle bar graphs of Figure 4) . Strikingly, 6 out of the 10 identified proteins (D13L, A7L, F13L, A6L, A10L and H5R) are within the 31 predominantly recognized proteins by CD4+ T cells (percentage of recognition >40%) and 5 (D13L, F13L, H5R, A10L and L1R) are within the 21 predominantly recognized proteins by antibodies (percentage of recognition >10%). Furthermore, the pie graphs represent the percentages of the predominantly recognized vaccinia proteins for which epitopes were identified using the two different approaches. These percentages suggest that in general T cell driven approaches are more effective than MHC approaches in identifying predominantly recognized vaccinia proteins. Table 1 shows the identity, temporal expression [8] and function of the most prevalently recognized proteins determined either by CD4+ T cell or antibody responses. Interestingly, most immunoprevalent proteins have late temporal expression which is in agreement to reported findings that show that CD8+ responses preferentially recognize antigens that are expressed early during the viral lifecycle whereas CD4+ T cell responses revealed a significant preference for late proteins (reviewed in [9] . The analysis described above suggests that "T cell driven" approaches, and in particular the strategy presented here, identify peptides derived from highly immunoprevalent vaccinia proteins. We then performed a statistical analysis comparing the probability of these findings to random sampling. For example, if a random sample of 10 proteins were selected from the 180 proteins analyzed by CD4+ T cell responses, the probability that 6 or more would be among the 31 predominantly recognized proteins would be only 0.21%. Similarly, if a random sample of 10 proteins were selected from the 181 proteins analyzed by antibody responses, the probability that 5 or more would be among the 21 predominantly recognized proteins would be 0.23%. The percentage of predominantly recognized proteins that we identified is about 60%, which is clearly larger than the random probabilities, and indeed the above probabilities indicate that the method used in the present study yields results significantly better than random selection.
Conclusions
A clear limitation in the discovery and evaluation of immunoprevalent antigens is the fact that the approaches are based first on the pre-selection of pathogen proteins or peptide antigens, and then on the identification of positive responses in bulk T cell populations. In contrast, our approach does not require a priori knowledge of pathogen antigens, and is not restricted by HLA haplotype. The approach presented here can be used to identify potential immunodominant and subdominant epitopes (and their corresponding proteins) to detect and induce parasite specific immune responses in upon infection or immunization. Furthermore, the parasite proteins identified are by definition immunogenic in humans, as they are recognized by T cells expanded in vivo during infection or vaccination.
Our results support the notion that the cytokines selected to profile CD4+ T cell specific responses should not rely only on IFN-γ secreting cells, but on assessing multi-cytokines at different time-points and by using different readout technologies. We believe that further efforts in the development of miniature T cell activation assays will be very beneficial to reduce the number of clonal CD4+ T cells required to test positional scanning libraries and to define the spectrum of specificities with higher throughput. In summary, we show that the single pathogen in vitro stimulation, the evaluation of pathogen specificity by detecting multiple cytokines, and the screening of T cell clones with positional scanning libraries using GM-CSF as readout of activation constitutes a novel approach for the elucidation of prevalently recognized proteins in response to large pathogens in human samples.
